.John D. Mendlein, Ph.D., J.D. is an Executive Partner of Flagship Pioneering, a venture capital firm. Prior to joining Flagship, Dr. Mendlein served as President, Corporate and Product Strategy, of Moderna, Inc., a clinical stage biotechnology company. Dr. Mendlein also serves as a member of the board of aTyr Pharma, Inc., and previously served as its Chief Executive Officer and Executive Chairman of the board of directors. He also holds board positions with The BIO (Biotechnology Industry Organization) emerging companies board and Editas Medicine, Inc., a genome editing company. Dr. Mendlein previously served as the Chief Executive Officer of Adnexus Therapeutics, Inc., a biopharmaceutical company, which was purchased by Bristol-Myers Squibb (BMY) in 2008. Dr. Mendlein also served on the board of directors of Monogram Biosciences, Inc., an HIV and oncology diagnostic company that was acquired by Laboratory Corporation of America Holdings in 2009. Before that, he served as Chairman and Chief Executive Officer of Affinium Pharmaceuticals Ltd. (acquired by Debiopharm Group), and board member, General Counsel and Chief Knowledge Officer at Aurora Bioscience Corporation (acquired by Vertex Pharmaceuticals, Inc.). Dr. Mendlein holds a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in biology from the University of Miami.